<<  <  >  >>

Page 48

that products available in these major overseas markets are

any less safe than products available in the United States."

66. Michael I. Krauss, "Loosening the FDA's Drug Certifica-

tion Monopoly," George Mason Law Review 4(1996): 457-483 at

p. 477.

67. Ibid., p. 477.

68. John Calfee, "The Leverage Principle in FDA's Regulation

of Information," in Competitive Strategies in the Pharmaceu-

tical Industry, ed. R. Helms, quoted in ibid., p. 472.

Published by the Cato Institute, Policy Analysis is a

regular series evaluating government policies and offering

proposals for reform. Nothing in Policy Analysis should be

construed as necessarily reflecting the views of the Cato

Institute or as an attempt to aid or hinder the passage of

any bill before Congress.

Contact the Cato Institute for reprint permission.Printed

copies of Policy Analysis are $6.00 each ($3.00 each for

five or more). To order, or for a complete listing of

available studies, write to: Cato Institute, 1000

Massachusetts Avenue NW, Washington, DC, 20001.(202)842-0200

FAX (202)842-3490 E-mail cato@cato.org